Opinion|Videos|January 23, 2025
Seamless Transitions: Supporting Patients Through Treatment, Monitoring, and Maintenance
Panelists discuss how industry-provided patient support services can assist patients receiving bispecific antibodies, particularly in monitoring and follow-up care, and how these services can support patients transitioning from active treatment to maintenance or posttreatment care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role would these services play in assisting patients receiving bispecific antibodies, particularly regarding monitoring and follow-up care to ensure optimal outcomes?
- How can industry-provided patient support services help patients transition from active treatment to maintenance or posttreatment care?
Advertisement
Related to this article
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
4
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
5